Literature DB >> 30455416

Extramedullary hematopoiesis in the absence of myeloproliferative neoplasm: Mayo Clinic case series of 309 patients.

N Fan1, S Lavu1, C A Hanson2, A Tefferi3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30455416      PMCID: PMC6242913          DOI: 10.1038/s41408-018-0156-6

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN: 2044-5385            Impact factor:   11.037


× No keyword cloud information.
Extramedullary hematopoiesis (EMH) implies the production of erythroid and myeloid progenitor cells outside of the bone marrow. EMH in adults is typically seen in patients with myeloproliferative neoplasms (MPNs) but its association also with other conditions, including thalassemia, has long been recognized[1]. In both MPN and non-MPN settings, the liver and spleen are the two most frequent sites of EMH and it has been hypothesized that circulating hematopoietic cell filtration (entrapment), possibly via endothelial cell expressed ligands, such as chemokine ligand 12, rather than splenic stroma account for the particular phenomenon[2-4]; the concordant detection of MPN-specific mutations, such as JAK2V617F, and specific cytogenetic abnormalities in both bone marrow and splenic tissue of affected patients, supports this contention[5,6]. Circulating hematopoietic progenitors mobilized as a result of otherwise nonspecific hematopoietic stressors have also been implicated in seeding non-hepatosplenic EMH (NHS-EMH)[7]. The latter has been reported in a variety of organs, including the central nervous system[8], ovaries and tubes[9], the skin[10], the lungs and pleura[11], the pericardium[12,13], lymph nodes[14], and other sites. In a previously published report of 27 Mayo Clinic cases of NHS-EMH diagnosed antemortem between 1975 and 2002[15], the most common associated condition was myelofibrosis and the most frequent involved site the thoracic vertebral column. The current study focuses on the Mayo Clinic experience with EMH cited in the absence of MPN. The objectives were to systematically describe associated conditions and involved sites and identify “idiopathic” cases and review their management and long-term outcome. After approval by the Mayo Clinic institutional review board, institutional databases were screened through the Mayo Clinic Advanced Cohort Explorer (ACE) Tool, in order to identify patients with EMH. ACE is a clinical data repository maintained by the Unified Data Platform; ACE is enriched with multiple source patient information including patient demographics, diagnosis, hospital notes, laboratory reports, flowsheets, pathology reports, and clinical notes. With ACE’s text search functionality, we queried “extramedullary hematopoiesis” or “EMH”. We performed a retrospective database review of all identified patients between 1975 and 2018. Demographic, biochemical, genetic, radiological, and pathological data were collected and reviewed. ACE identified 1933 cases of “EMH”. Extensive review confirmed the absence of associated MPN in 336 cases. Among these, 27 cases involved pathology remarks during tissue biopsy for liver transplant and were excluded from further analysis. The most frequent associated conditions in the remaining 309 cases (Table 1) included myelodysplastic syndromes (MDS) (n = 41; 13%); acute myeloid leukemia (AML) (n = 28; 9%); hemolytic anemia (n = 24; 8%); thalassemia (n = 22; 7%); non-Hodgkin’s lymphoma (NHL), with excess cases with splenic marginal zone lymphoma (n = 19; 6%); immune thrombocytopenic purpura (ITP) (n = 17; 6%); metastatic cancer, with breast cancer being the most frequent (n = 17; 6%); plasma cell neoplasms, including polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes (n = 12; 4%); hereditary spherocytosis (n = 8; 3%); cirrhosis (n = 7; 2%); acute lymphoblastic leukemia (n = 6; 2%); chronic lymphocytic leukemia (n = 6; 2%); Hodgkin’s lymphoma (n = 5; 2%); and a spectrum of other hematologic and non-hematologic conditions with less than five incident cases, including large granular lymphocyte and natural killer cell disorders, chronic myelomonocytic leukemia, hemophagocytic lymphohistiocytosis, anemia of chronic disease, bone marrow failure syndrome, and fungal or viral infection including human immunodeficiency virus and cytomegalovirus; in 12 (4%) cases, no overt associated condition was evident and the cases were accordingly assigned “idiopathic” EMH (further elaborated below). The most frequently involved sites included the spleen (n = 164; 53%), liver (n = 78; 25%), lymph nodes (n = 20; 6%), and the para-spinal region (n = 16; 5%) (Table 1). Other sites with lower number of incident cases included the pre-sacral, retroperitoneal, and mediastinal regions, the skull, maxillary region, the skin, kidneys, adrenal tissue, thyroid gland, ovaries, lung, heart, pleura, and pericardium.
Table 1

Associated conditions and involved sites among 309 cases of extramedullary hematopoiesis in the absence of myeloproliferative neoplasms

Associated conditionsInvolved sites
SpleenLiverLymph nodesPara-spinal regionRetroperitoneal regionPre-sacral regionLungHeartMediastinal regionOther sites
All patients (n = 309)1647820165783234
Myelodysplastic syndromes (n = 41)23841102006
Acute myeloid leukemia (n = 28)12831001106
Hemolytic anemia (n = 24)22200100000
Thalassemia (n = 22)11404111014
Non-Hodgkin’s lymphoma (n = 19)15200000002
Immune thrombocytopenic purpura (n = 17)15120000000
Metastatic cancer (n = 17)3731001003
Plasma cell neoplasms (n = 12)4510010002
Hereditary spherocytosis (n = 8)5002010000
Cirrhosis (n = 7)2500000000
Acute lymphoblastic leukemia (n = 6)3210000000
Chronic lymphocytic leukemia (n = 6)2112000000
Hodgkin’s lymphoma (n = 5)2310001001
“Idiopathic” EMH (n = 12)2003142000
Others (n = 93)4330421002110
Associated conditions and involved sites among 309 cases of extramedullary hematopoiesis in the absence of myeloproliferative neoplasms A diagnosis of “idiopathic” EMH was established in 12 (4%) patients (median age 71 years, range 23–78; 50% females). Most of these cases presented with nonspecific symptoms including abdominal and back pain and the EMH was an incidental discovery (Table 2); 1 patient with splenic EMH presented with fever of unidentified origin (FUO). Involved sites in the 12 patients with idiopathic EMH included 4 pre-sacral, 3 para-spinal, 2 spleen, and 1 each retroperitoneal, pleural-based chest mass, and right upper lobe lung mass. All idiopathic EMH cases were evaluated with imaging studies and diagnosis was subsequently confirmed by pathology review. Past medical history was non-contributory. Complete blood counts were normal in 7 cases, showed anemia in 4 cases, and were not available in 1 case (Table 2). The median follow-up time since the discovery of idiopathic EMH was 7 years (range 2–20). None of the patients with idiopathic EMH showed evidence of any malignancy, including MPN or other hematologic disorders, either at presentation or during follow-up. Nine (75%) of the 12 patients with idiopathic EMH were managed conservatively; the 2 patients with splenic EMH underwent splenectomy and 1 patient had surgical excision of the EMH mass in order to prevent compression of the ureter. The FUO in the patient with splenic EMH resolved with splenectomy.
Table 2

Characteristics of 12 consecutive patients with idiopathic EMH

Age/sexPresentationDiagnostic proceduresInvolved sitesHemoglobin, g/dlLeukocyte count, ×109/lPlatelet count, ×109/lManagementFollow-up since discovery of EMH (years)
71/FAbdominal painMRI, FNAPre-sacral mass13.44.4320Conservative9
62/MInterstitial pneumoniaWedge biopsiesRight upper lobe lung massN/AN/AN/AConservative4
23/MFUOPET, splenectomySplenomegaly11.16252Surgical excision9
78/FGallstone evaluationMRI, FNABPre-sacral mass14.16.1157Conservative7
72/MSacral chordomaCT, FNABPleural-based chest mass11.44.7131Conservative4
50/MBack painCT, FNABLeft retroperitoneal mass15.411.9310Surgical excision2
72/FRecurrent UTIMRI, FNABPre-sacral mass9.3a10.5431Conservative5
58/FPara-spinal massPET, FNAPara-spinal mass107.5295Conservative7
71/FDyspneaCT, FNAPara-spinal mass14.29.6222Conservative4
76/FAbdominal painCT, FNAPre-sacral mass14.25.8244Conservative10
61/FSplenomegalyCT, splenectomySplenomegaly16.57.6187Surgical excision17
70/FBack painCT, FNAPara-spinal mass14.87.8171Conservative20

EMH extramedullary hematopoiesis, FNA fine needle aspiration, FNAB fine needle aspiration and biopsy, FUO fever of unidentified origin, MRI magnetic resonance imaging, N/A not available, PET positron emission tomography, CT computed tomography, UTI urinary tract infection

aPatient was confirmed to have iron deficiency anemia and was successfully treated with iron supplement

Characteristics of 12 consecutive patients with idiopathic EMH EMH extramedullary hematopoiesis, FNA fine needle aspiration, FNAB fine needle aspiration and biopsy, FUO fever of unidentified origin, MRI magnetic resonance imaging, N/A not available, PET positron emission tomography, CT computed tomography, UTI urinary tract infection aPatient was confirmed to have iron deficiency anemia and was successfully treated with iron supplement We present the largest experience in EMH without associated MPN, in adults. We confirm the spleen and liver being by far the most frequent organs involved; MDS, AML, hemolytic anemia, thalassemia, NHL, ITP, metastatic cancer, and plasma cell neoplasms constituted the most frequent associated conditions. Considering the lack of information, we were particularly interested in “idiopathic” EMH and its natural history. We identified 12 cases of idiopathic EMH, which often represented an incidental discovery during evaluation of unrelated symptoms. None of the patients with idiopathic EMH harbored occult malignancies or subsequently developed MPN or other myeloid malignancies. Accordingly, our observations do not support undertaking extensive investigations targeting MPN or other malignancies in idiopathic EMH and simple monitoring might be adequate.
  15 in total

1.  Extramedullary hematopoiesis involving the central nervous system and surrounding structures.

Authors:  Viktor Zherebitskiy; Carmen Morales; Marc R Del Bigio
Journal:  Hum Pathol       Date:  2011-04-14       Impact factor: 3.466

2.  Cardiac tamponade in myelofibrosis: A Mayo clinic series of nine consecutive cases.

Authors:  Sravanthi Lavu; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2017-07-19       Impact factor: 10.047

Review 3.  Cardiac tamponade resulting from pericardial extramedullary hematopoiesis: a case report and review of the literature.

Authors:  G M Pipoly; J Rogers
Journal:  Cancer       Date:  1979-10       Impact factor: 6.860

4.  27-Hydroxycholesterol induces hematopoietic stem cell mobilization and extramedullary hematopoiesis during pregnancy.

Authors:  Hideyuki Oguro; Jeffrey G McDonald; Zhiyu Zhao; Michihisa Umetani; Philip W Shaul; Sean J Morrison
Journal:  J Clin Invest       Date:  2017-08-07       Impact factor: 14.808

5.  Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia.

Authors:  R A Mesa; C Y Li; G Schroeder; A Tefferi
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

Review 6.  Extramedullary hematopoiesis and myeloid metaplasia of the ovaries and tubes in a patient with myelofibrosis: case report and concise review of the reported cases.

Authors:  Benoît Rabischong; Demetrio Larraín; Cécile Charpy; Pierre J Déchelotte; Gérard Mage
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

7.  The pathogenesis of splenic extramedullary hematopoiesis in metastatic carcinoma.

Authors:  J C O'Keane; B C Wolf; R S Neiman
Journal:  Cancer       Date:  1989-04-15       Impact factor: 6.860

8.  Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis.

Authors:  Sergej Konoplev; Pin-Pen Hsieh; Chung-Che Chang; L Jeffrey Medeiros; Pei Lin
Journal:  Hum Pathol       Date:  2007-08-20       Impact factor: 3.466

Review 9.  Extramedullary hematopoiesis: Elucidating the function of the hematopoietic stem cell niche (Review).

Authors:  Kouhei Yamamoto; Yukako Miwa; Shiho Abe-Suzuki; Shinya Abe; Susumu Kirimura; Iichiroh Onishi; Masanobu Kitagawa; Morito Kurata
Journal:  Mol Med Rep       Date:  2015-11-27       Impact factor: 2.952

10.  Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment.

Authors:  Cody A Koch; Chin-Yang Li; Ruben A Mesa; Ayalew Tefferi
Journal:  Mayo Clin Proc       Date:  2003-10       Impact factor: 7.616

View more
  10 in total

1.  Extramedullary Hematopoiesis in Lymphangioma - A Cytological Study.

Authors:  Pritika Kushwaha; Meeta Singh; Shyama Jain; Sujoy Neogi
Journal:  J Cytol       Date:  2021-05-15       Impact factor: 1.000

2.  Immunological consequences of extramedullary erythropoiesis: immunoregulatory functions of CD71+ erythroid cells.

Authors:  Shokrollah Elahi; Siavash Mashhouri
Journal:  Haematologica       Date:  2020-04-30       Impact factor: 9.941

3.  15-PGDH inhibition activates the splenic niche to promote hematopoietic regeneration.

Authors:  Julianne Np Smith; Dawn M Dawson; Kelsey F Christo; Alvin P Jogasuria; Mark J Cameron; Monika I Antczak; Joseph M Ready; Stanton L Gerson; Sanford D Markowitz; Amar B Desai
Journal:  JCI Insight       Date:  2021-03-22

4.  An Unusual Case of Myelodysplastic Syndrome With Intrahepatic Extramedullary Hematopoiesis Leading to Liver Failure.

Authors:  Logan Ternes; Faye Giangiacomo; Imad Nassif
Journal:  Cureus       Date:  2022-03-01

5.  An 80-year-old woman with myelofibrosis and diffuse mosaic attenuation on chest computed tomography.

Authors:  Harpreet Singh; Jonathan S Kurman; Chinmay T Jani; Nagarjun Rao; Bryan S Benn
Journal:  Respir Med Case Rep       Date:  2022-07-11

6.  A case report of a rare omental extramedullary hematopoiesis in an adult: 'an idiopathic finding'.

Authors:  Tarek Haykal; Anitha Yelangi; Trailokya Pandit; Ghassan Bachuwa; Qazi Azher
Journal:  Oxf Med Case Reports       Date:  2019-12-31

Review 7.  Contribution of Extramedullary Hematopoiesis to Atherosclerosis. The Spleen as a Neglected Hub of Inflammatory Cells.

Authors:  Victoria Fernández-García; Silvia González-Ramos; Paloma Martín-Sanz; Antonio Castrillo; Lisardo Boscá
Journal:  Front Immunol       Date:  2020-10-26       Impact factor: 7.561

Review 8.  Extramedullary Hematopoiesis of the Liver and Spleen.

Authors:  Diana Cenariu; Sabina Iluta; Alina-Andreea Zimta; Bobe Petrushev; Liren Qian; Noemi Dirzu; Ciprian Tomuleasa; Horia Bumbea; Florin Zaharie
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

9.  Perturbed hematopoiesis in individuals with germline DNMT3A overgrowth Tatton-Brown-Rahman syndrome.

Authors:  Ayala Tovy; Carina Rosas; Amos S Gaikwad; Geraldo Medrano; Linda Zhang; Jaime M Reyes; Yung-Hsin Huang; Tastuhiko Arakawa; Kristen Kurtz; Shannon E Conneely; Anna G Guzman; Rogelio Aguilar; Anne Gao; Chun-Wei Chen; Jean J Kim; Melissa T Carter; Amaia Lasa-Aranzasti; Irene Valenzuela; Lionel Van Maldergem; Lorenzo Brunetti; M John Hicks; Andrea N Marcogliese; Margaret A Goodell; Rachel E Rau
Journal:  Haematologica       Date:  2022-04-01       Impact factor: 11.047

10.  Sex Matters: Physiological Abundance of Immuno-Regulatory CD71+ Erythroid Cells Impair Immunity in Females.

Authors:  Siavash Mashhouri; Petya Koleva; Mai Huynh; Isobel Okoye; Shima Shahbaz; Shokrollah Elahi
Journal:  Front Immunol       Date:  2021-07-21       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.